Cannabis may interact with blood thinners and antiplatelet drugs through liver enzyme competition
A review of 665 screened articles identified potential interactions between cannabis and anticoagulants/antiplatelets, including THC increasing warfarin levels via CYP2C9 inhibition and CBD potentially reducing clopidogrel effectiveness via CYP2C19 inhibition.
Quick Facts
What This Study Found
Cannabis components can inhibit liver enzymes (CYP2C9, CYP2C19) and transporters involved in metabolizing blood thinners. Case reports showed cannabis inhibited warfarin metabolism, increasing INR and bleeding risk. CBD may reduce conversion of clopidogrel to its active form, potentially increasing stroke risk.
Key Numbers
665 articles screened, 6 relevant publications identified. THC inhibits CYP2C9 (warfarin metabolism). CBD inhibits CYP2C19 (clopidogrel activation). Case reports documented increased INR with cannabis-warfarin co-use.
How They Did This
Review screening 665 articles from PubMed and EMBASE. Six relevant publications were identified: 4 case reports, 1 in vitro study, and 1 pharmacokinetic article.
Why This Research Matters
Patients using blood thinners for cardiac conditions, stroke prevention, or post-stent management are at high risk from drug interactions. With increasing medical and recreational cannabis use, clinicians need to be aware of these potential interactions.
The Bigger Picture
These interactions highlight a gap in patient counseling: patients on life-critical medications like warfarin or clopidogrel may not be asked about cannabis use, and cannabis users may not realize the risks of combining it with their prescribed medications.
What This Study Doesn't Tell Us
Very limited direct evidence (only 6 relevant publications). Most data comes from case reports and in vitro studies. Clinical significance of these interactions in real-world dosing is not well established.
Questions This Raises
- ?Should patients on blood thinners receive routine counseling about cannabis interactions?
- ?How clinically significant are these interactions at typical cannabis doses?
- ?Should INR monitoring be increased in warfarin patients who use cannabis?
Trust & Context
- Key Stat:
- THC inhibits CYP2C9 (warfarin); CBD inhibits CYP2C19 (clopidogrel)
- Evidence Grade:
- Moderate: plausible pharmacological mechanisms supported by case reports, but very limited clinical data.
- Study Age:
- Published in 2020 in Journal of Clinical Pharmacology.
- Original Title:
- A Review of Cannabis and Interactions With Anticoagulant and Antiplatelet Agents.
- Published In:
- Journal of clinical pharmacology, 60(4), 432-438 (2020)
- Authors:
- Greger, Jessica, Bates, Vernice, Mechtler, Laszlo(4), Gengo, Fran
- Database ID:
- RTHC-02587
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Can I use cannabis while taking blood thinners?
This review identifies potential risks. THC may increase warfarin levels, raising bleeding risk, while CBD may reduce clopidogrel effectiveness. Patients on these medications should discuss cannabis use with their prescribing physician.
How strong is the evidence?
The evidence is limited to a few case reports and laboratory studies. The pharmacological mechanisms are plausible, but large clinical studies have not been done to determine how often these interactions cause actual problems.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
- thc-and-blood-pressure-medication-interactions
- thc-and-caffeine-most-common-drug-combo
Cite This Study
https://rethinkthc.com/research/RTHC-02587APA
Greger, Jessica; Bates, Vernice; Mechtler, Laszlo; Gengo, Fran. (2020). A Review of Cannabis and Interactions With Anticoagulant and Antiplatelet Agents.. Journal of clinical pharmacology, 60(4), 432-438. https://doi.org/10.1002/jcph.1557
MLA
Greger, Jessica, et al. "A Review of Cannabis and Interactions With Anticoagulant and Antiplatelet Agents.." Journal of clinical pharmacology, 2020. https://doi.org/10.1002/jcph.1557
RethinkTHC
RethinkTHC Research Database. "A Review of Cannabis and Interactions With Anticoagulant and..." RTHC-02587. Retrieved from https://rethinkthc.com/research/greger-2020-a-review-of-cannabis
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.